Publications by authors named "Alberto Vasconcelos"
Article Synopsis
- Oral azacitidine (Oral-AZA) is recommended for maintenance therapy in newly diagnosed acute myeloid leukemia (ND AML) patients who are not transplant candidates after achieving remission with intensive chemotherapy, while venetoclax plus injectable azacitidine (VEN-AZA) is suggested for those ineligible for intensive chemotherapy.
- A retrospective study utilized Flatiron Health's database to compare treatment effects and outcomes of Oral-AZA maintenance after intensive chemotherapy versus frontline treatment with VEN-AZA.
- Results showed that patients in the Oral-AZA group had better relapse-free survival (14.9 months) and overall survival (18.7 months) compared to those receiving VEN-AZA, indicating a significant advantage for Oral-AZA in this
Lenalidomide in Transfusion-Dependent IPSS Low- or Intermediate-1-Risk Myelodysplastic Syndromes and Isolated Del(5q): Results of a European Postauthorization Safety Surveillance Study.
Clin Lymphoma Myeloma Leuk
October 2024
Article Synopsis
- This study evaluated the safety and effectiveness of lenalidomide in patients with transfusion-dependent myelodysplastic syndromes (MDS) associated with a specific genetic deletion (del[5q]), focusing on its use in routine clinical care from 2014 to 2022.
- A total of 296 patients were involved, with key findings showing a 24-month cumulative incidence of acute myeloid leukemia (AML) progression at 12.7% and an overall survival probability of 78.3% at 24 months.
- The study reported that over two-thirds of patients experienced serious side effects, with 35.5% discontinuing treatment due to these adverse events, but no new safety issues were identified
Introduction: The substantial economic burden of acute myeloid leukemia (AML) could be reduced with post-remission maintenance therapies that delay relapse. Real-world healthcare resource utilization (HCRU) data and costs among patients with AML receiving oral azacitidine (Oral-AZA) maintenance therapy or no maintenance are not well understood. We characterize HCRU and costs among these patients in clinical practice in the USA.
View Article and Find Full Text PDFIntensive chemotherapy (IC) is commonly used to achieve remission in patients with acute myeloid leukemia (AML). Venetoclax plus azacitidine (VEN-AZA) is FDA-approved to treat patients with AML aged ≥ 75 years or who are ineligible for IC. This retrospective analysis used de-identified electronic health records from the US-based Flatiron Health database from patients diagnosed 11/21/2018 to 10/31/2021 to compare treatment outcomes with VEN-AZA vs.
View Article and Find Full Text PDFBackground And Objectives: The significant reduction in postoperative thromboembolic complications has been attributed to the use of regional block, probably due to attenuation of the neuroendocrine-metabolic response. Pregnant women, who demonstrate important hypercoagulability, can in theory benefit from this effect during labor. The objective of this study was to determine the effects of regional block on coagulation of pregnant women.
View Article and Find Full Text PDFObjective: To evaluate the advantages and disadvantages of microlaparoscopy vs. conventional laparoscopy in the management of patients with early-stage pelvic endometriosis.
Study Design: In this prospective, randomized study we evaluated 54 patients with a clinical diagnosis of stage I and II pelvic endometriosis according to the classification of the American Society for Reproductive Medicine, revised in 1996.